Abstract
PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.
| Original language | English |
|---|---|
| Pages (from-to) | 123-131 |
| Number of pages | 9 |
| Journal | Clinical interventions in aging |
| Volume | 5 |
| Publication status | Published - Jan 1 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Geriatrics and Gerontology
Cite this
Alendronate improves QOL of postmenopausal women with osteoporosis. / Kawate, Hisaya; Keizo, Ohnaka; Adachi, Masahiro; Kono, Suminori; Ikematsu, Hideyuki; Matsuo, Hisashi; Higuchi, Kazumi; Takayama, Takehiko; Takayanagi, Ryoichi.
In: Clinical interventions in aging, Vol. 5, 01.01.2010, p. 123-131.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alendronate improves QOL of postmenopausal women with osteoporosis.
AU - Kawate, Hisaya
AU - Keizo, Ohnaka
AU - Adachi, Masahiro
AU - Kono, Suminori
AU - Ikematsu, Hideyuki
AU - Matsuo, Hisashi
AU - Higuchi, Kazumi
AU - Takayama, Takehiko
AU - Takayanagi, Ryoichi
PY - 2010/1/1
Y1 - 2010/1/1
N2 - PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.
AB - PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.
UR - http://www.scopus.com/inward/record.url?scp=77955297766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955297766&partnerID=8YFLogxK
M3 - Article
VL - 5
SP - 123
EP - 131
JO - Clinical Interventions in Aging
JF - Clinical Interventions in Aging
SN - 1176-9092
ER -